Effectiveness of oral ondansetron on revisits and hospital admissions in children aged 1–6 years with acute gastroenteritii̇s: a retrospective cohort study
Abstract
Objective: Acute gastroenteritis remains an important public health problem worldwide, particularly in childhood, and continues to impose a clinical and economic burden on healthcare systems. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that was initially developed for the prevention of chemotherapy-induced nausea and vomiting. In recent years, oral ondansetron has been increasingly used in children with acute gastroenteritis. The aim of this study was to evaluate the association between oral ondansetron use and emergency department revisit and hospital admission rates in children aged 1–6 years with acute gastroenteritis.Material and Methods:This retrospective cohort study included 339 children aged 1–6 years who presented with symptoms of acute gastroenteritis to the Pediatric Emergency Department of Acibadem Maslak Hospital between January 2022 and November 2024. Patients were divided into two groups: those who received oral ondansetron (n=162) and those who did not receive any antiemetic treatment (control group, n=177). Demographic and clinical data were obtained from electronic medical records. Rates of emergency department revisits, hospital admissions, and intravenous fluid requirement were compared between the groups.Results:The rate of emergency department revisit within 7 days was 14% in the ondansetron group and 21% in the control group (p=0.036). Hospital admission rates were lower in the ondansetron group compared with the control group (2%…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 339 participants or records.
Read the paper
Related studies
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Treatment of norovirus infections: moving antivirals from the bench to the bedside
- Abstracts of the 2012 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 25 May–1 June 2012, London, UK
- Global Research Trends in Irritable Bowel Syndrome: A Bibliometric and Visualized Study
- Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.